Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2010

Open Access 01-12-2010 | Review

Clinical use of biomarkers of survival in pulmonary fibrosis

Authors: Michiel Thomeer, Jan C Grutters, Wim A Wuyts, Stijn Willems, Maurits G Demedts

Published in: Respiratory Research | Issue 1/2010

Login to get access

Abstract

Background

Biologic predictors or biomarkers of survival in pulmonary fibrosis with a worse prognosis, more specifically in idiopathic pulmonary fibrosis would help the clinician in deciding whether or not to treat since treatment carries a potential risk for adverse events. These decisions are made easier if accurate and objective measurements of the patients' clinical status can predict the risk of progression to death.

Method

A literature review is given on different biomarkers of survival in interstitial lung disease, mainly in IPF, since this disease has the worst prognosis.

Conclusion

Serum biomarkers, and markers measured by medical imaging as HRCT, pertechnegas, DTPA en FDG-PET are not ready for clinical use to predict mortality in different forms of ILD. A baseline FVC, a change of FVC of more than 10%, and change in 6MWD are clinically helpful predictors of survival.
Literature
1.
Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994, 150:967–972.CrossRefPubMed
2.
3.
American Thoracic Society (ATS) and the European Respiratory Society (ERS): Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000, 161:646–664.CrossRef
4.
British Thoracic Society recommendations: The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999,54(Suppl 1):S1–30.
5.
Wilson JW, du Bois RM, King TE Jr: Challenges in pulmonary fibrosis: 8--The need for an international registry for idiopathic pulmonary fibrosis. Thorax 2008, 63:285–287.CrossRefPubMed
6.
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al.: The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005, 142:963–967.CrossRefPubMed
7.
Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ: Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998, 351:24–27.CrossRefPubMed
8.
Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, et al.: Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179:717–723.CrossRefPubMed
9.
Fung ET, Wright GL Jr, Dalmasso EA: Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2000, 2:643–650.PubMed
10.
Wikipedia: Biomarker. 22–5-2009. 23–5-2009
11.
12.
Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, et al.: Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002, 19:439–446.CrossRefPubMed
13.
Takahashi H, Fujishima TA, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al.: Serum Surfactant Proteins A and D as Prognostic Factors in Idiopathic Pulmonary Fibrosis and Their Relationship to Disease Extent. Am J Respir Crit Care Med 2000, 162:1109–1114.CrossRefPubMed
14.
Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, et al.: Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis. Chest 2009, 135:1557–1563.CrossRefPubMedPubMedCentral
15.
Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989, 96:68–73.CrossRefPubMed
16.
Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, et al.: Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001, 93:97–106.CrossRefPubMed
17.
Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M: Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000, 161:589–594.CrossRefPubMed
18.
Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al.: Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998, 55:307–319.CrossRefPubMed
19.
Inoue Y, Nishimura K, Shiode M, Akutsu H, Hamada H, Fujioka S, et al.: Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Tuber Lung Dis 1995, 76:230–233.CrossRefPubMed
20.
Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, et al.: Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158:1680–1684.CrossRefPubMed
21.
Janssen R, Grutters JC, Sato H, van Velzen-Blad H, Zanen P, Kohno N, et al.: Analysis of KL-6 and SP-D as disease markers in bird fancier's lung. Sarcoidosis Vasc Diffuse Lung Dis 2005, 22:51–57.PubMed
22.
Nakashima T, Yokoyama A, Ohnishi H, Hamada H, Ishikawa N, Haruta Y, et al.: Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. J Intern Med 2008, 263:432–439.CrossRefPubMed
23.
Kohno N, Yokoyama A, Kondo K: KL-6 as a serum marker for amiodarone-induced pulmonary toxicity. Intern Med 2000, 39:1004–1005.CrossRefPubMed
24.
Cobben NA, Drent M, Schols AM, Lamers RJ, Wouters EF, Van Dieijen-Visser MP: Serum lactate dehydrogenase and its isoenzyme pattern in ex-coalminers. Respir Med 1997, 91:616–623.CrossRefPubMed
25.
Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M: Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 1996, 9:1736–1742.CrossRefPubMed
26.
Drent M, Cobben NA, Van Dieijen-Visser MP, Braat SH, Wouters EF: Serum lactate dehydrogenase activity: indicator of the development of pneumonitis induced by amiodarone. Eur Heart J 1998, 19:969–970.CrossRefPubMed
27.
Matusiewicz SP, Williamson IJ, Sime PJ, Brown PH, Wenham PR, Crompton GK, et al.: Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis? Eur Respir J 1993, 6:1282–1286.PubMed
28.
van Krugten M, Cobben NA, Lamers RJ, Van Dieijen-Visser MP, Wagenaar SS, Wouters EF, et al.: Serum LDH: a marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis. Neth J Med 1996, 48:220–223.CrossRefPubMed
29.
30.
Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al.: A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006, 173:781–792.CrossRefPubMed
31.
Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, et al.: CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007, 56:1685–1693.CrossRefPubMed
32.
Thomeer MJ, Vansteenkiste J, Verbeken EK, Demedts M: Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. Respir Med 2004, 98:567–573.CrossRefPubMed
33.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al.: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229–2242.CrossRefPubMed
34.
Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al.: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350:125–133.CrossRefPubMed
35.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al.: Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543–548.CrossRefPubMed
36.
Erbes R, Schaberg T, Loddenkemper R: Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997, 111:51–57.CrossRefPubMed
37.
Jezek V, Fucik J, Michaljanic A, Jezkova L: The prognostic significance of functional tests in cryptogenic fibrosing alveolitis. Bull Eur Physiopathol Respir 1980, 16:711–720.PubMed
38.
Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, et al.: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994, 149:450–454.CrossRefPubMed
39.
Rudd RM, Haslam PL, Turner-Warwick M: Cryptogenic fibrosing alveolitis: Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981, 124:1–8.PubMed
40.
Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM, Coultas DB: Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998, 53:469–476.CrossRefPubMedPubMedCentral
41.
Hanson D, Winterbauer RH, Kirtland S, Wu R: Changes in pulmonary function test: results after 1 year of therapy as predictors of survival in patients with pulmonary fibrosis. Chest 1995, 108:305–310.CrossRefPubMed
42.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.: Standardisation of spirometry. Eur Respir J 2005, 26:319–338.CrossRefPubMed
43.
Miller A, Elliott JC, Thornton JC, Warshaw R, Geiger M, Anderson H: Comparison of spirometry performed on the same subjects by two teams using similar instruments: an investigation of variability in prevalence of impairment. Environ Res 1980, 21:229–234.CrossRefPubMed
44.
45.
Schwartz DA, Van Fossen D, Davis C, Helmers RA, Dayton CS, Burmeister L, et al.: Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994, 149:444–449.CrossRefPubMed
46.
Schwartz DA, Van Fossen D, Davis C, Helmers RA, Dayton CS, Burmeister L, et al.: Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the lung study group. Am J Respir Crit Care Med 1998, 158:220–225.CrossRef
47.
Raghu G, DePaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al.: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind, randomized, placebo-controlled trial. Am Rev Respir Dis 1991, 144:291–296.CrossRefPubMed
48.
Raghu G, Craig JW, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999, 159:1061–1069.CrossRefPubMed
49.
Zanen P, van der LL, van der MT, van den Bosch JM: Reference values for alveolar membrane diffusion capacity and pulmonary capillary blood volume. Eur Respir J 2001, 18:764–769.CrossRefPubMed
50.
Aguilaniu B, Maitre J, Glenet S, Gegout-Petit A, Guenard H: European reference equations for CO and NO lung transfer. Eur Respir J 2008, 31:1091–1097.CrossRefPubMed
51.
O'Donnell D: Physiology of interstitial lung disease. In Interstitial lung disease. Edited by: Schwarz MI, King TE Jr. Hamilton, ON, Canada: Decker Inc; 1998:51–70.
52.
du Bois RM: Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010, 9:129–140.CrossRefPubMed
53.
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al.: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374:222–228.CrossRefPubMed
54.
Fleischmann R: Primer: establishing a clinical trial unit - regulations and infrastructure. Nat Clin Pract Rheumatol 2007, 3:234–239.CrossRefPubMed
55.
Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, et al.: The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010, 65:173–177.CrossRefPubMed
56.
Holland AE, Hill CJ, Conron M, Munro P, McDonald CF: Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009, 103:1430–1435.CrossRefPubMed
57.
Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF: The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 2006, 100:1734–1741.CrossRefPubMed
58.
Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S: Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009, 103:117–123.CrossRefPubMed
59.
Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G: The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005, 25:96–103.CrossRefPubMed
60.
Eaton T, Young P, Milne D, Wells AU: Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005, 171:1150–1157.CrossRefPubMed
61.
Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM: Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:659–664.CrossRefPubMedPubMedCentral
62.
du Bois RM, Albera C, Costabel U, Bradford WZ, Kartashov A, Noble PW, Szwarcberg J, Thomeer M, Valeyre D, Weycker D, King TE: 6 minute walk test distance is a reliable, valid and responsive outcome measure that predicts mortality in patients with IPF. Am J Respir Crit Care Med 2010, 181:A1103.
63.
Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM: The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993, 148:1076–1082.CrossRefPubMed
64.
Leung AN, Miller RR, Muller NL: Parenchymal opacification in chronic infiltrative lung diseases: CT-pathologic correlation. Radiology 1993, 188:209–214.CrossRefPubMed
65.
Lee JS, Im JG, Ahn JM, Kim YM, Han MC: Fibrosing alveolitis: prognostic implication of ground-glass attenuation at high-resolution CT. Radiology 1992, 184:451–454.CrossRefPubMed
66.
Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A: Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993, 189:693–698.CrossRefPubMed
67.
Hansell DM, Wells AU: CT evaluation of fibrosing alveolitis--applications and insights. J Thorac Imaging 1996, 11:231–249.CrossRefPubMed
68.
Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al.: High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992, 47:738–742.CrossRefPubMedPubMedCentral
69.
Gay SE, Kazerooni EA, Toews GB, Lynch JP III, Gross BH, Cascade PN, et al.: Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998, 157:1063–1072.CrossRefPubMed
70.
Mouratidis B, Lising J, Nogrady S, Hurwitz M: Increased pertechnegas lung clearance in interstitial lung disease. Clin Nucl Med 1999, 24:105–108.CrossRefPubMed
71.
72.
Barrowcliffe MP, Jones JG: Pulmonary clearance of 99m Tc-DTPA in the diagnosis and evolution of increased permeability pulmonary oedema. Anaesth Intensive Care 1989, 17:422–432.PubMed
73.
Kon OM, Daniil Z, Black CM, du Bois RM: Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J 1999, 13:133–136.CrossRefPubMed
74.
Thomeer MJ, Dehaes B, Mortelmans L, Demedts M: Pertechnegas lung clearance in different forms of interstitial lung disease. Eur Respir J 2002, 19:31–36.CrossRefPubMed
75.
Keijsers RG, Verzijlbergen FJ, Oyen WJ, van den Bosch JM, Ruven HJ, van Velzen-Blad H, et al.: 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009, 36:1131–1137.CrossRefPubMed
76.
Langah R, Spicer K, Gebregziabher M, Gordon L: Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009, 16:801–810.CrossRefPubMed
77.
Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC: Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007, 132:1949–1953.CrossRefPubMed
78.
Ryu JH, Daniels CE, Hartman TE, Yi ES: Diagnosis of interstitial lung diseases. Mayo Clin Proc 2007, 82:976–986.CrossRefPubMed
Metadata
Title
Clinical use of biomarkers of survival in pulmonary fibrosis
Authors
Michiel Thomeer
Jan C Grutters
Wim A Wuyts
Stijn Willems
Maurits G Demedts
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2010
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-11-89

Other articles of this Issue 1/2010

Respiratory Research 1/2010 Go to the issue

Research

Regional differences in prediction models of lung function in Germany

Research

Pharmacological studies of the mechanism and function of interleukin-1β-induced miRNA-146a expression in primary human airway smooth muscle

Research

No evidence of altered alveolar macrophage polarization, but reduced expression of TLR2, in bronchoalveolar lavage cells in sarcoidosis

Research

Potential mechanisms underlying the acute lung dysfunction and bacterial extrapulmonary dissemination during Burkholderia cenocepacia respiratory infection

Research

PPARγ deficiency results in reduced lung elastic recoil and abnormalities in airspace distribution

Research

Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits